(R)-(+)-(3,4-二甲氧基)苯-1-苯基乙胺 | 134430-93-6

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (R)-(+)-(3,4-二甲氧基)苯-1-苯基乙胺
• 中文别名: (-)-(S)-N-(3,4-二甲氧基苄基)-(1-苯基乙基)胺
• 英文名称: (R)-N-(3,4-dimethoxybenzyl)-N-(α-methylbenzyl)amine
• 英文别名: (R)-N-3,4-dimethoxybenzyl-N-(α-methylbenzyl)amine；(R)-N-3,4-dimethoxy benzyl-N-α-methylbenzylamine；(R)-N-3,4-dimethoxybenzyl-N-α-methylbenzylamine；(R)-3,4-dimethoxy-N-(1-phenylethyl)benzylamine；(R)-N-(3,4-dimethoxybenzyl)-1-phenylethanamine；VEP；(1R)-N-[(3,4-dimethoxyphenyl)methyl]-1-phenylethanamine
• CAS: 134430-93-6
• 化学式: C₁₇H₂₁NO₂
• 分子量: 271.359
• InChiKey: UPMJXBLRDCBHGF-CYBMUJFWSA-N

物化性质

• 熔点：
  158 - 162°C
• 沸点：
  414.44°C (rough estimate)
• 密度：
  1.0288 (rough estimate)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）
• 稳定性/保质期：
  <p>遵照规定使用和储存，则不会分解。</p>

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37,S39
• 危险类别码：
  R36/37/38
• 海关编码：
  2922299090
• 储存条件：
  存储于阴凉干燥处。

SDS

Name:	(R)-(+)-(3 4-Dimethoxy)benzyl-1-phenylethylamine 98% Material Safety Data Sheet
Synonym:	None
CAS:	134430-93-6

Section 1 - Chemical Product MSDS Name:(R)-(+)-(3 4-Dimethoxy)benzyl-1-phenylethylamine 98% Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
134430-93-6	(R)-(+)-(3,4-Dimethoxy)benzyl-1-phenyl	98	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 134430-93-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Viscous liquid
Color: clear yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C17H21NO2
Molecular Weight: 271.36

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
No specific conditions to avoid noted.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 134430-93-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(R)-(+)-(3,4-Dimethoxy)benzyl-1-phenylethylamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 134430-93-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 134430-93-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 134430-93-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  酮基布洛芬 、 (R)-(+)-(3,4-二甲氧基)苯-1-苯基乙胺 在 溶剂黄146 、 sodium hydroxide 作用下， 以 水 为溶剂， 以47%的产率得到
  参考文献：
  名称：

  (±)-2-(3-苯甲酰基)-苯基丙酸的拆分方法

  摘要：

  本发明提供一种(±)‑2‑(3‑苯甲酰基)‑苯基丙酸的拆分方法，该方法使用所述(±)‑2‑(3‑苯甲酰基)‑苯基丙酸碱盐为原料，以所述(R)‑3,4‑二甲氧基‑N‑(1‑苯乙基)‑苯甲胺酸盐做拆分剂，在溶剂水存在的条件下进行反应，得到S‑(+)‑2‑(3‑苯甲酰基)‑苯基丙酸与(R)‑3,4‑二甲氧基‑N‑(1‑苯乙基)‑苯甲胺的非对映体盐，即拆分盐，然后用酸将得到的拆分盐游离，可获得S‑(+)‑2‑(3‑苯甲酰基)‑苯基丙酸。本发明提供的(±)‑2‑(3‑苯甲酰基)‑苯基丙酸的拆分方法，该方法在拆分盐的形成过程中，无需使用有机溶剂，使用水做溶剂。另外，拆分剂的用量降低了近50％。因而，是一个更加具备优势的拆分工艺。

  公开号：

  CN107759466B
• 作为产物：
  描述：

  R(+)-alpha-甲基苄胺 、 3,4-二甲氧基苯甲醛 在 sodium tetrahydroborate 、 iron(III) trifluoromethanesulfonate 作用下， 以 二氯甲烷 为溶剂， 反应 0.08h， 以90%的产率得到(R)-(+)-(3,4-二甲氧基)苯-1-苯基乙胺
  参考文献：
  名称：

  三氟甲磺酸铁使用硼氢化钠催化醛的还原胺化

  摘要：

  描述了一种在催化量的Fe（OTf）3存在下使用NaBH 4进行醛还原胺化反应的有效简便方法。

  DOI：

  10.1016/j.tetlet.2012.06.018

文献信息

• Asymmetric total synthesis of sperabillins B and D via lithium amide conjugate addition
  作者：Stephen G. Davies、Jane R. Haggitt、Osamu Ichihara、Richard J. Kelly、Michael A. Leech、Anne J. Price Mortimer、Paul M. Roberts、Andrew D. Smith

  DOI：10.1039/b404962d

  日期：——

  Diastereoselective conjugate addition of homochiral lithium (R)-N-allyl-N-alpha-methylbenzylamide to methyl (2E,5E)-hepatadienoate, followed by protecting group manipulation and subsequent iodocyclocarbamation allows a concise route to the core fragment, methyl (3R,5R,6R)-3,6-diamino-5-hydroxyheptanoate, of sperabillins B and D. Differentiation between the C-3 and C-6 primary amino groups of this core

  将非手性锂（R）-N-烯丙基-N-α-甲基苄基酰胺的非对映选择性共轭加成到（2E，5E）-庚二烯酸甲酯中，然后进行保护基团处理，然后进行碘代环氨基甲酸酯化，可以得到通往核心片段甲基（3R，脂蛋白B和D的5R，6R）-3,6-二氨基-5-羟基庚酸酯。通过用丙酮处理，很容易实现该核心氨基酸的C-3和C-6伯氨基之间的区分。 ，6-异亚丙基和C-3-亚胺保护的二胺，随后C-6-氮的区域选择性酰化促进了总产率为10.8％的斯培比林D的总合成，以及首次总产率为5.8％的斯培比林B的不对称合成。 。
• A systematic study of the solid state and solution phase conformational preferences of β-peptides derived from C(3)-alkyl substituted transpentacin derivatives
  作者：Elin Abraham、Timothy D.W. Claridge、Stephen G. Davies、Barbara Odell、Paul M. Roberts、Angela J. Russell、Andrew D. Smith、Lorna J. Smith、Helen R. Storr、Miles J. Sweet、Amber L. Thompson、James E. Thomson、George E. Tranter、David J. Watkin

  DOI：10.1016/j.tetasy.2010.12.007

  日期：2011.1

  preference of the parent pentamer and hexamer derived from 2-aminocyclopentanecarboxylic acid (transpentacin) residues in both the solid state and solution phase. Evidence for the alternative turn type conformation identified for the C(3)-unsubstituted tetramer was not observed in the C(3)-alkyl substituted derivatives, consistent with the alkyl substituent anti to the amino functionality destabilising this

  已经使用多种光谱学和晶体学技术研究了衍生自一系列2-氨基-3-烷基环戊烷羧酸残基的一系列同源的β-肽的固态和溶液相构象偏好。这些研究表明，Ç（3） -烷基取代的反式对环戊烷骨架上的氨基被由2-氨基环戊烷羧酸衍生的亲本五聚体和六既定12螺旋的二级结构优选耐受（transpentacin）在这两个残基固态和固溶相。证据确定了C（3）未被取代的四聚体替代转式构象中，没有观察到C ^（3）-烷基取代的衍生物，与抗氨基官能团的烷基取代基一致，该官能团使该基序不稳定。这些结果表明，基于transpentacin支架的低聚物可能更适合在C（3）处对氨基进行抗修饰，并保留了二级结构。
• Homochiral lithium amides for the asymmetric synthesis of β-amino acids
  作者：Stephen G. Davies、Narciso M. Garrido、Dennis Kruchinin、Osamu Ichihara、Luke J. Kotchie、Paul D. Price、Anne J. Price Mortimer、Angela J. Russell、Andrew D. Smith

  DOI：10.1016/j.tetasy.2006.05.008

  日期：2006.7

  Secondary homochiral lithium amides derived from α-methylbenzylamine undergo highly diastereoselective conjugate additions to a range of α,β-unsaturated esters. The corresponding β-amino acids are readily liberated by successive N-debenzylation and ester hydrolysis, furnishing (R)-β-amino butyric acid, (R)-β-amino pentanoic acid, (S)-β-leucine, (R)-β-amino octanoic acid, (S)-β-phenylalanine, (S)-β-tyrosine

  衍生自α-甲基苄胺的仲手性锂酰胺会经历高度非对映选择性的共轭加成反应，形成一系列α，β-不饱和酯。通过连续的N-去苄基化和酯水解，可以轻松释放相应的β-氨基酸，从而提供（R）-β-氨基丁酸，（R）-β-氨基戊酸，（S）-β-亮氨酸，（R） -β-氨基辛酸，（S）-β-苯丙氨酸，（S）-β-酪氨酸甲基醚，（S）-β-酪氨酸盐酸盐和（S）-β-（2-甲氧基苯基）-β-氨基丙酸高产和高ee的酸。该程序在天然产物合成中的应用（R证明了）-β-DOPA和（R）-β-赖氨酸。还描述了简化的一锅反应规程的开发，该规程适用于同级手性β-氨基酯的多克规模合成。
• Production method of (R) -3 hydroxy-3- (2-phenylethyl) hexanoic acid and intermediate thereof
  申请人：Sumika Fine Chemicals Co., Ltd.

  公开号：US20030176507A1

  公开（公告）日：2003-09-18

  The present invention relates to a production method of (R)-3-hydroxy-3-(2-phenylethyl)hexanoic acid which comprises optical resolution of racemic 3-hydroxy-3-(2-phenylethyl)hexanoic acid with an optically active amine of the formula (VIII) 1 wherein R 2 is 3,4-dimethoxyphenyl or 2-chlorophenyl. According to the present invention, (R)-3-hydroxy-3-(2-phenylethyl)hexanoic acid useful as a starting material of a pharmaceutical agent can be efficiently produced with a high optical purity and a relatively high total yield.

  本发明涉及(R)-3-羟基-3-(2-苯乙基)己酸的生产方法，包括用具有光学活性的式(VIII)中的氨基对混合的3-羟基-3-(2-苯乙基)己酸进行光学分辨，其中R2为3,4-二甲氧基苯基或2-氯苯基。根据本发明，作为制药剂的起始物质(R)-3-羟基-3-(2-苯乙基)己酸可以高效地生产，具有高光学纯度和相对较高的总产率。
• Stereoselective conjugate addition reactions of lithium amides to α,β-unsaturated chiral iron acyl complexes [(η5-C5H5)Fe(CO)(PPh3)(COCHCHR)]
  作者：Stephen G. Davies、Jairton Dupont、Robert J.C. Easton、Osamu Ichihara、Jeffrey M. McKenna、Andrew D. Smith、José A.A. de Sousa

  DOI：10.1016/j.jorganchem.2004.04.046

  日期：2004.11

  Conjugate addition of achiral lithium dimethylamide to the chiral iron cinnamoyl complexes (S,E)- and (S,Z)-[(η5-C5H5)Fe(CO)(PPh3)(COCHCHPh)] proceeds with high diastereoselectivity, with this protocol being used to establish unambiguously the absolute configuration of Winterstein’s acid (3-N,N-dimethylamino-3-phenylpropanoic acid) as (R). The highly diastereoselective conjugate addition of lithium

  共轭加成的非手性二甲基氨基锂的手性铁络合物肉桂（小号，ë） -和（小号，Ž） - [（η 5 -C 5 H ^ 5）的Fe（CO）（PPH 3）（COCHCHPh）]进行以高非对映选择性，使用该方案可以明确地确定温特斯坦酸（3- N，N-二甲基氨基-3-苯基丙酸）的绝对构型为（R）。锂N-苄基-N的高度非对映选择性共轭加成-三甲基甲硅烷基酰胺形成一系列α，β-不饱和铁酰基络合物，然后通过烷基化或醛醇缩合反应原位合成衍生的烯酸酯，这也促进了顺式和反式-β-内酰胺的立体选择性合成。该方法已被用于实现（±）-橄榄酸和（±）-硫霉素的形式不对称合成。手性氨基化锂的添加来自伯和仲胺衍生的铁巴豆络合物[（η 5 -C 5 H ^ 5）的Fe（CO）（PPH 3）（COCHCHMe）]表示锂Ñ -α-甲基苄显示低水平的对映体识别，而锂N-3,4-二甲氧基苄Ñ -α-甲基苄基酰胺和锂Ñ苄基Ñ -α-甲基苄